Skip to main content
OpenTrials

Clinical trial condition

Relapsed or Refractory Multiple Myeloma

Explore clinical trials studying Relapsed or Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

44 public trials 13 recruiting studies
Refine in advanced search Browse all conditions

Relapsed or Refractory Multiple Myeloma trial results

Completed

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic Florida Jacksonville, Florida, United States
  • Mayo Clinic Minnesota Rochester, Minnesota, United States
  • Icahn School of Medicine New York, United States
  • University of Pennsylvania, Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

NCT01058434

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. Mobile, Alabama, United States
  • Central Hematology Oncology Medical Group Alhambra, California, United States
  • Central Coast Medical Oncology Corporation Santa Maria, California, United States
  • St. Jude Heritage Medical Group Virginia Crosson Cancer Center Yorba Linda, California, United States
View all 30 locations
View Trial Details
Completed

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic - Arizona Cancer Clinical Research Unit Scottsdale, Arizona, United States
  • Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3) San Antonio, Texas, United States
  • Novartis Investigative Site Melbourne, Australia
  • Novartis Investigative Site Frankfurt, Germany
View Trial Details
Completed

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

NCT01866293

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States
View Trial Details
Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

NCT00478777

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Medizinische Klinik und Poliklinik II der Charité Universitätsmedizin Berlin Campus Mitte Berlin, Germany
  • Poliklinik I, Hämatologie/ Onkologie, Universitätsklinikum Bonn Bonn, Germany
  • Johanniter-Krankenhaus Bonn Friedrich-Wilhelm-Stift gGmbH Bonn, Germany
  • Medizinische Klinik Städtisches Klinikum Braunschweig gGmbH Braunschweig, Germany
View all 48 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Princess Margaret Hospital Toronto, Ontario, Canada
  • Jewish General Hospital Montreal, Quebec, Canada
  • Seoul National University Hospital Seoul, South Korea
  • Asan Medical Center Seoul, South Korea
View all 15 locations
View Trial Details

Related conditions